Atlas Trials

IPSS Risk Category Intermediate-2

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch IPSS Risk Category Intermediate-2

RecordFirmDate
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome (NCT03047993)M.D. Anderson Cancer Center2017-11-15

Track IPSS Risk Category Intermediate-2 automatically

Every clearance here is in the API, with alerts when new ones post.